Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data

Plus, news about Novartis. 🤝 Pfizer turns over ADC: The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known as PF-08046031, a Seagen-derived asset that it ...